Abie Abebaw, Damessa Mekonnen
Department of Pharmacy, College of Medicine and Health Science, Debre-Markos University, Debre-Markos, Ethiopia.
Department of Pharmacy, Institute of Health, Jimma University, Jimma, Ethiopia.
HIV AIDS (Auckl). 2023 Aug 9;15:457-475. doi: 10.2147/HIV.S421523. eCollection 2023.
Despite the high prevalence of age-associated comorbidities in HIV patients in sub-Saharan Africa, there is a lack of data on their influence on treatment outcomes in HIV patients. Therefore, this study aimed to assess the impact of age-associated comorbidities on responses to antiretroviral therapy (ART) among people living with HIV.
A hospital-based nested case-control study was conducted among adult HIV-infected patients at the Jimma Medical Center from January 3 to June 2, 2022. Data were recorded by interviewing the patients and their medical chart and analyzed using The Statistical Package for Social Science (SPSS) v. 23, and at p <0.05.
The overall immunological and virologic failure rates were 13.8% and 13.4%, respectively. Being male [AOR = 3.079,95% CI (1.139-8.327)], having age-associated comorbidity [AOR:10.57,95% CI (2.810-39.779)], age ≥ 50 years [AOR = 2.855, 95% CI (1.023-7.9650)], alcohol intake [AOR = 3.648,95% CI (1.118-11.897)], and having a baseline CD4+ count of < 200 cells/uL [AOR:3.862, 95% CI (1.109-13.456) were an independent predictor of immunological failure; Whereas Being alcoholic [AOR:3.11, 95% CI (1.044-9.271)], having a baseline CD4+ count of < 200 cells/uL [AOR:5.11, 95% CI (1.547-16.892)], a low medication adherence [AOR:5.92, 95% CI (1.81-19.36)], bedridden baseline functional status [AOR:3.902, 95% CI (1.237-12.307)], and lack of cotrimoxazole prophylaxis [AOR:2.735,95% CI (1.084-6.902)] were found to be an independent predictor of virologic treatment failure, but being younger (age < 50 years) was protective for virologic failure.
Out of the eight patients who were treated for HIV at least one patient had developed immunological and/or virological failure. Age-associated comorbid chronic non-communicable diseases highly influence immunological outcomes compared with virological outcomes. Health providers should pay attention to age-associated comorbidities, encourage lifestyle modifications, and counsel on medication adherence to improve clinical outcomes in patients with HIV.
尽管撒哈拉以南非洲地区的艾滋病毒患者中与年龄相关的合并症患病率很高,但缺乏关于这些合并症对艾滋病毒患者治疗结果影响的数据。因此,本研究旨在评估与年龄相关的合并症对艾滋病毒感染者抗逆转录病毒治疗(ART)反应的影响。
2022年1月3日至6月2日,在吉姆马医疗中心对成年艾滋病毒感染患者进行了一项基于医院的巢式病例对照研究。通过对患者及其病历进行访谈记录数据,并使用社会科学统计软件包(SPSS)v.23进行分析,p<0.05。
总体免疫和病毒学失败率分别为13.8%和13.4%。男性[AOR = 3.079,95%CI(1.139 - 8.327)]、患有与年龄相关的合并症[AOR:10.57,95%CI(2.810 - 39.779)]、年龄≥50岁[AOR = 2.855,95%CI(1.023 - 7.9650)]、饮酒[AOR = 3.648,95%CI(1.118 - 11.897)]以及基线CD4+细胞计数<200个/微升[AOR:3.862,95%CI(1.109 - 13.456)]是免疫失败的独立预测因素;而酗酒[AOR:3.11,95%CI(1.044 - 9.271)]、基线CD4+细胞计数<200个/微升[AOR:5.11,95%CI(1.547 - 16.892)]、药物依从性低[AOR:5.92,95%CI(1.81 - 19.36)]、卧床不起的基线功能状态[AOR:3.902,95%CI(1.237 - 12.307)]以及缺乏复方新诺明预防[AOR:2.735,95%CI(1.084 - 6.902)]被发现是病毒学治疗失败的独立预测因素,但较年轻(年龄<50岁)对病毒学失败有保护作用。
在接受艾滋病毒治疗的8名患者中,至少有1名患者出现了免疫和/或病毒学失败。与病毒学结果相比,与年龄相关的合并慢性非传染性疾病对免疫结果的影响更大。医疗服务提供者应关注与年龄相关的合并症,鼓励改变生活方式,并就药物依从性提供咨询,以改善艾滋病毒患者的临床结果。